Abstracts tagged "innate immunity and juvenile idiopathic arthritis (JIA)"

Abstract Number: 1462 • 2015 ACR/ARHP Annual Meeting
Farber Disease: Important Differential Diagnostic Information for JIA and Other Inflammatory Arthritis Phenotypes Is Revealed By Data from the Largest Clinical Cohort to Date
Alexander Solyom¹, Boris Huegle², Bo Magnusson³, Balahan Makay⁴, Nur Arslan⁵, John Mitchell⁶, Pranoot Tanpaiboon⁷, Norberto Guelbert⁸, Ratna Puri⁹, Lawrence Jung¹⁰, Giedre Grigelioniene¹¹, Karoline Ehlert¹², Michael Beck¹³, Calogera Simonaro¹⁴ and Edward Schuchman¹⁵, ¹Pediatrics, University of Pecs, Pecs, Hungary, ²Pediatric Rheumatology, German Center for Pediatric and Adolescent Rheumatology, Garmisch-Partenkirchen, Germany, ³Pediatric Rheumatology, Karolinska University Hospital, Stockholm, Sweden, ⁴Pediatric Rheumatology, Eylul University, Izmir, Turkey, ⁵Eylul University, Izmir, Turkey, ⁶Pediatric Endocrinology, Montreal Children's Hospital, Montreal, QC, Canada, ⁷Genetics and Metabolism, Children's National Medical Center, Washington, DC, ⁸Metabolic Diseases Section, Children’s Hospital of Cordoba, Cordoba, Argentina, ⁹Medical Genetics, Sir Ganga Ram Hospital, New Delhi, India, ¹⁰Pediatric Rheumatology, Children's National Med Ctr, Washington, DC, ¹¹Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden, ¹²University Medical Center - Greifswald, Greifswald, Germany, ¹³Institute of Human Genetics, University Medical Center - Mainz, Mainz, Germany, ¹⁴Genetics and Genomic Sciences, Icahn School of Medicine at Mt. Sinai, New York, NY, ¹⁵Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Farber disease (Farber lipogranulomatosis; acid ceramidase deficiency) is a rare lysosomal storage disorder resulting from the inherited deficiency of the enzyme acid ceramidase due…
Abstract Number: 2299 • 2014 ACR/ARHP Annual Meeting
M-Ficolin and Masp-2 As Inflammatory Markers in Oligoarticular and Systemic Juvenile Idiopathic Arthritis
Christine Petri¹, Steffen Thiel², Jens Christian Jensenius² and Troels Herlin¹, ¹Pediatric Rheumatology Clinic, Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark, ²Biomedicine, Aarhus University, Aarhus, Denmark
Background/Purpose The lectin pathway of the complement plays a crucial role in the pathogenesis of various inflammatory processes. The lectin pathway proteins are activated through…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].